Phase Ib/II trial of multiple escalating doses of ITI 007 for the treatment of patients with stable schizophrenia.

Trial Profile

Phase Ib/II trial of multiple escalating doses of ITI 007 for the treatment of patients with stable schizophrenia.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 30 Jul 2010

At a glance

  • Drugs Lumateperone (Primary)
  • Indications Schizophrenia
  • Focus Adverse reactions
  • Sponsors Intra-Cellular Therapies
  • Most Recent Events

    • 30 Jul 2010 Primary endpoints of 'safety and tolerability' have been met; results reported in an Intra-Cellular Therapies media release.
    • 30 Jul 2010 Status changed to completed according to Intra-Cellular Therapies media release
    • 30 Jul 2010 Results have been reported in an Intra-Cellular Therapies media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top